[1] | Al-mozaini M, Mansour MK, Al-hokail A. HIV-Care Outcome in Saudi Arabia; a Longitudinal Cohort. J AIDS Clin Res 2014; 5(11): 370. |
|
[2] | Collazos J, Asensi V, Carton JA (2007) Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. AIDS 21: 835-843. |
|
[3] | WHO Report: impact of antiretroviral on the incidence opportunistic infections in resource-limited setting: A systemic review and meta -2013. |
|
[4] | Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006; 3689534: 505-510. |
|
[5] | Ford D, Robins JM, Petersen ML. The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models. Am J Epidemiol 2015; 182(7): 633-643. |
|
[6] | Tang H, Mao Y, Shi CS. Baseline CD4 Cell Counts of Newly Diagnosed HIV Cases in China: 2006-2012. PLOS Journals 2014; 9(6): e96098. |
|
[7] | Kilaru KR, Kumar A, Sippy N. CD4 cell counts in adults with newly diagnosed HIV infection in Barbados, CSIELO Public Health 2004; 16(5):302-7. |
|
[8] | Kim SG, Gerver SM, Fidler S. Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis. AIDS 2014; 28(13):1945-1956. |
|
[9] | Van Der Linden D, Lapointe N, Ransy DG, Motorina A, Soudeyns H, Lamarre V. Portrait of antiretroviral drug resistance in HIV-1-infected adolescents prior to their transfer to adult care: an exploratory study. Canad J Infect Dis Med Microbiol 2011; 22: 13B. |
|
[10] | Eisen S, Barkley L, Schepers C, Gurney K, Clapson M, Shingadia D, et al. Impact of transition to adult services on clinic attendance and virological control in HIV-infected adolescents. HIV Med2009; 10:45. |
|
[11] | Ellis J, Norrish G, Elgalib A. HIV positive adolescents: characteristics and treatment challenges. HIV Med 2012; 13:38. |
|
[12] | Memish ZA, Al-tawfiq JA, Filemban SM. Antiretroviral therapy, CD4, viral load, and disease stage in HIV patients in Saudi Arabia: a 2001-2013 cross-sectional study, J Infect Dev Ctries 2015; 9(7):765-769. |
|
[13] | Alrajhi AA, Halim MA, Al-Abdely HM (2006) Presentation and reasons for HIV-1 testing in Saudi Arabia. Int J STD AIDS 17: 806-809. |
|
[14] | Mazroa MA, Kabbash IA, Felemban SM, Stephens GM, AlHakeem RF, Zumla AI, Memish ZA (2012) HIV case notification rates in the Kingdom of Saudi Arabia over the past decade (2000-2009). PloS One 7: e45919. |
|
[15] | Al-Mazrou YY, Abouzeid MS, Al-Jeffri MH (2005) Impact of health education on knowledge and attitudes of Saudi paramedical students toward HIV/AIDS. Saudi Med J 26: 1788-1795. |
|
[16] | Rubaihayo J, Tumwesigye NM, Konde-lule J. Trends in prevalence of selected opportunistic infections associated with HIV/AIDS in Uganda. BMC Infectious Diseases 2015; 15(187):1471-2334. |
|
[17] | Staine JG. AIDS up date 2007: An overview of acquired immune deficiency syndrome. New York McGraw-Hill co., Inc; 2008. |
|
[18] | Bruno R, Sacchi P, Filice G: Overview on the incidence and the characteristics of HIV-related opportunistic infections and neoplasms of the heart: impact of highly active antiretroviral therapy. |
|
[19] | Warszawski J, de Wit S, Zangerle R, Fabre-Colin C, et al.: The Incidence of AIDS-Defining Illnesses at a Current CD4 Count > =200 Cells/μL in the Post-Combination Antiretroviral Therapy Era. |
|
[20] | HIV-related opportunistic infections. MBJ best practice [homepage on the Internet]. 2013 [cited 2015 Dec 1]. Available from: http://bestpractice.bmj.com/best-practice/monograph/899/basics/epidemiology.html. |
|
[21] | Saeed NK, Farid E, Jamsheer AE. Prevalence of opportunistic infections in HIV-positive patients in Bahrain: a four-year review (2009-2013), J Infect Dev Ctries 2015; 9(1):060-069. |
|
[22] | Kingston ME, Harder EJ, Al-Jaberi MM, Bailey TM, Roberts GT, et al. Acquired immune deficiency syndrome in the Middle East from imported blood. Transfusion. 1985; 25:317-318. |
|
[23] | Closing the gap in HIV prevention and treatment. [homepage on the Internet]. 2014 [cited 2015 Dec 1]. Available from, Saudi Ministry of Health Web site: /http://www.moh.gov.sa. |
|
[24] | Delmas MC, Jadand C, De Vincenzi I, Deveau C, Persoz A, Sobel A, et al. Gender difference in CD4+ cell counts persist after HIV-1 infection. SEROCO Study Group. AIDS 1997; 11:1071-1073. |
|
[25] | Finkel DG, John G, Holland B, Slim J, Smith SM. Women have a greater immunological response to effective virological HIV-1 therapy. AIDS 2003; 17:2009-2011. |
|
[26] | Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defic Syndr 2000; 24:475-482. |
|
[27] | Prins M, Robertson JR, Brettle RP, Aguado IH, Broers B, Boufassa F, et al. Do gender differences in CD4 cell counts matter? AIDS 1999; 13:2361-2364. |
|
[28] | WHO guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV- September 2015. |
|